Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
Trump Buys SpaceX Shares After Record IPO 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Nvidia Options Price in $280 Billion Earnings Swing 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Ampol Profit Surges as Refining Margins Hit Record Highs 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Tesla Raises Cybertruck Prices by $5,000 in US 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Add as a preferred source on Google
DUBLIN, Ireland, May 01, 2018 -- Prothena Corporation plc (Nasdaq:PRTA), a clinical-stage biotechnology company focused on the discovery and development of novel therapies in the neuroscience and orphan categories, will announce financial results for the first quarter of 2018 on May 8, 2018 after the close of the U.S. financial markets.
Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on May 8.
About Prothena
Prothena Corporation plc is a global clinical-stage biotechnology company focused on the discovery and development of novel therapies in the neuroscience and orphan categories. Fueled by its deep scientific understanding built over decades of research in protein misfolding, Prothena seeks to fundamentally change the course of progressive, life-threatening diseases associated with this biology. Prothena is advancing a pipeline of antibody therapeutic candidates for a number of indications and novel targets including Parkinson's disease and other related synucleinopathies (PRX002/RG7935) and ATTR amyloidosis (PRX004), as well as tau, Aβ (Amyloid beta), TDP-43 and ALECT2, where its scientific understanding of disease pathology can be leveraged. For more information, please visit the Company's website at www.prothena.com and follow us @ProthenaCorp.
Media & Investor Contact:
Ellen Rose, Head of Communications
650-922-2405, [email protected]
